Related Experiment Videos
Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction
C A Campbell1, C F Clavenna, J Wynne
1Division of Cardiology, Harper Hospital, Detroit, Michigan 48201.
Insights
Pentoxifylline, a haemorrheological agent, did not reduce infarct size in a canine model of acute myocardial infarction. This study found no significant effect on myocardial blood flow or necrosis, indicating limited therapeutic potential in this context.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Myocardial Infarction Models
Background:
- Acute myocardial infarction (MI) remains a leading cause of mortality worldwide.
- Investigating novel therapeutic agents to limit infarct size and improve outcomes is crucial.
- Pentoxifylline is a haemorheological agent with potential anti-inflammatory and blood flow-improving properties.
Purpose of the Study:
- To evaluate the efficacy of pentoxifylline in reducing infarct size in a canine model of acute myocardial infarction.
- To assess the impact of pentoxifylline on myocardial blood flow and collateral circulation.
- To determine if pentoxifylline influences hemodynamic parameters during acute MI.
Main Methods:
- An acute myocardial infarction model was induced in dogs by occluding the left anterior descending coronary artery for 6 hours.
- Dogs were randomized to receive either intravenous pentoxifylline or a control solution.
- Infarct size was quantified using monastral blue dye and triphenyltetrazium chloride staining; regional myocardial blood flow was measured using radioactive microspheres.
Main Results:
- The area at risk and the area of necrosis were not significantly different between the pentoxifylline-treated group and the control group.
- Necrosis as a percentage of the area at risk was similar in both groups.
- Pentoxifylline did not significantly alter heart rate, blood pressure, or regional myocardial blood flow.
Conclusions:
- Pentoxifylline does not reduce infarct size in this canine model of acute myocardial infarction.
- The drug did not enhance coronary collateral blood flow during the experimental MI.
- These findings suggest that pentoxifylline may not be an effective therapeutic agent for limiting myocardial damage in acute MI.
Abstract:
1. The effect of the haemorrheological agent pentoxifylline was investigated in a canine model of acute myocardial infarction, induced by occlusion of the left anterior descending coronary for 6 h. Thirty minutes post-occlusion the dogs were randomized to receive either distilled water or pentoxifylline (0.3 mg kg-1 min-1 for 1 h followed by 0.15 mg kg-1 min-1 for 4.5 h) intravenously. 2. At 6 h post-occlusion the in vivo area at risk was determined with monastral blue dye and the area of necrosis was determined with triphenyltetrazolium chloride. The area at risk was 16.5 +/- 1.3% in the control group (n = 10) and 17.2 +/- 1.8% in the pentoxifylline treated group (n = 10; NS). The area of necrosis was 12.3 +/- 1.9% in the control group and 11.9 +/- 2.2% in the pentoxifylline treated group (NS). The area of necrosis expressed as a percentage of the area at risk was 69.3 +/- 7.7% in the control group and 63.6 +/- 7.4% in the pentoxifylline treated group (NS). 3. Pentoxifylline had no significant effects on heart rate, systolic or diastolic blood pressure. Regional myocardial blood flow, measured by the radioactive microsphere technique, was not significantly different between the groups. 4. Thus, pentoxifylline does not reduce infarct size in this model of acute myocardial infarction and does not enhance coronary collateral blood flow.